# A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy

> **NCT07540364** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Suven Life Sciences Limited** · enrollment: 240 (estimated)

## Conditions studied

- Narcolepsy

## Interventions

- **DRUG:** Samelisant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07540364
- **Lead sponsor:** Suven Life Sciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-19
- **Primary completion:** 2027-11-19
- **Final completion:** 2027-12-19
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07540364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07540364, "A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07540364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*